Onkuretherapeutics Is A Clinical Stagebiopharmaceutical Company Dedicated To Developing Precision Medicines For Cancerthecompany Focuses On Biologically Validated Drivers Of Cancerparticularly Thosethat Areunderserved By Current Therapiesonkureutilizes A Structurebased Drug Design Platform To Createtumor Agnostic Therapies That Areoptimized For Both Tolerability And Efficacy Thecompany Is Publicly Traded On Nasdaq Under Theticker Okur And Is Led By A Team Of Experienced Scientists In Drug Discovery And Developmentonkures Pipelineincludes Oki 219A Selectivepi Kih1047R Inhibitor Currently In Clinical Developmentand Several Other Pi Kiinhibitors Aimed At Improving Therapeutic Outcomesrecent Developments Includea Merger With Reneo Pharmaceuticals And A Strong Financial Positionwith Sufficient Funding To Support Operations Through Late2026Onkureis Committed To Advancing Next Generation Oncology Therapeuticsparticularly For Patients With Cancers Driven By Pi Kimutations
No conferences found for this company.
| Company Name | Reneo Pharma Ltd |
| Country |
United Kingdom
|
| Address | N/A |
| Telephone | N/A |
| N/A |
